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YKL-1, E1B 55 kDa-deleted recombinant adenovirus vec-
tor, capable of harboring a transgene casette of up to 4.9 kb,
was newly constructed by reintroducing E1A and E1B 19 kDa
into E1/E3-deleted adenoviral vector with a homologous re-
combination in E. coli. Virus replication and cytotoxicity were
dramatically attenuated in all 3 different types of normal
human cells. In contrast, YKL-1 efficiently replicated and
induced cytotoxicity in most cancer cells, especially Hep3B
and C33A cells with an inactivating p53 mutation. However,
both H460 and HepG2 exhibited intermediate sensitivity to
YKL-1, which was between that of Hep3B or C33A and nor-
mal human cells. The YKL-1 and DNA damaging agent,
camptothecin effectively induced p53 in H460 and HepG2 as
well as in normal cells. Furthermore, YKL-1 effectively pro-
hibited both Hep3B and C33A tumor growth in nu/nu mice in
a dose-dependent manner. H/E staining and TUNEL assay
indicated a largely distributed necrotic area and apoptosis on
its periphery. This study, therefore, indicates that YKL-1,
possesses promising potential as an oncolytic adenoviral vec-
tor, which acts partially in a p53-dependent manner. Int.
J. Cancer 88:454–463, 2000.
© 2000 Wiley-Liss, Inc.
E1/E3-deleted replication-defective adenovirus derived from hu-
man adenovirus type 5 (had5) has been widely used for cancer gene
therapy because it offers, in contrast to other vectors, much higher
gene transfer efficiency and transgene expression in a broad spectrum
of cell types (Jolly, 1994; Verma and Somia, 1997). Therapeutic
genes are generally inserted in place of the E1 gene, which is essential
for viral replication (Graham et al., 1987; Yee and Perricaudet, 1997;
Hitt et al., 1994). A variety of antitumoral genes including cytokines,
immune-costimulatory factors, suicide genes and tumor suppressor
genes have been applied, which has resulted in cancer cell death in
vitro and eventual tumor regression in vivo (Paillard, 1998; Roth and
Cristiano, 1997; Runnebaum, 1997). However, the therapeutic effi-
cacy of E1-deleted replication-incompetent adenovirus is limited by
its inability to spread in and infect neighboring cancer cells subse-
quent to the initial infection event.
Bischoff et al. in 1996 reported that E1B 55 kDa-attenuated
recombinant adenovirus (ONYX-015) preferentially replicated in
and killed cells lacking functional p53, including the majority of
human cancer cells. Subsequent study by Heise et al. demonstrated
ONYX-015 to be an effective antitumoral agent (oncolytic viral
agent) in vitro and in vivo (Heise et al., 1997). Furthermore, Kirn
et al. (1998) reported encouraging clinical data by administering
ONYX-015 intratumorally to patients with recurrent head and
neck cancer. E1 gene, one of the adenovirus early genes, encodes
multiple open reading frames, including E1A and E1B 55 kDa
(Graham et al., 1987; Shenk, 1996). E1A gene product, a tran-
scription factor, associates with pRB, p300 and other proteins, and
is largely responsible for driving infected cells into the S phase to
allow the synthesis of viral genome (Shenk, 1996; Shenk and Flint,
1991). E1A expression and unexpected foreign DNA synthesis
triggers the expression/activation of p53 (Lowe and Ruley, 1993;
Nakajima et al., 1998). In contrast, E1B 55 kDa physically asso-
ciates with and inactivates p53 (Yew and Berk, 1992; Joseph and
Vogt, 1996). By using this mechanism, wild-type adenovirus can
manipulate host cells to provide the optimal conditions for effec-
tive virus replication and production. Therefore, E1B 55 kDa
attenuated recombinant adenovirus should not be able to replicate
in normal human cells, whereas it would be able to replicate in
cells lacking functional p53.
p53 tumor suppressor gene is mutated in roughly 50% of human
cancers, including non-small cell lung, colon, breast, head and
neck, and ovarian cancers (Brennan et al., 1995; Bergh et al.,
1995; Perkins and Steern, 1997). Furthermore, in many other
human cancers encoding wild-type p53, p53 is not functional by
the overexpression of mdm2 (Leach et al., 1993; Marchetti et al.,
1995), human papilloma virus (HPV) infection (Scheffner et al.,
1990; Joseph and Vogt, 1996) or other unknown mechanisms
(Chang et al., 1995). Loss of functional p53 is well-correlated with
the later stages of most human cancers, such as poor prognosis and
resistance to conventional cancer therapy (Harris and Holstein,
1993; Kirsch and Kastan, 1998). However, the potential of E1B 55
kDa deleted adenovirus as an antitumoral reagent has been chal-
lenged by several reports, which has questioned its mechanistic
action against human cancer cells, especially with respect to p53
(Hall et al., 1998; Goldsmith et al., 1998; Goodrum and Ornelles,
1998; Rothmann et al., 1998; Harada and Berk, 1999; Hay et al.,
1999; Turnell et al., 1999).
In our study, we generated E1B 55 kDa-deleted recombinant ade-
novirus (YKL-1) by using a different strategy from ONYX-015 and
evaluated its feasibility as an antitumoral agent in vitro and in vivo.
The oncolytic potential of YKL-1 was investigated by examining
virus replication and cytotoxicity in 3 different types of normal human
cells as well as a variety of human cancer cells. The correlation of p53
status and the conditionally replicating capability of YKL-1 was
evaluated by examining endogenous p53 transcription activity and the
induction rate of p53 by DNA-damaging agents and YKL-1 infection.
Finally, the therapeutic efficacy of YKL-1 was analyzed in a nu/nu
mouse model bearing C33A and Hep3B xenografts.
MATERIAL AND METHODS
Cell lines
All the cell lines were maintained in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal bovine serum, L-
glutamine (2 mM), penicillin (100 IU/ml) and streptomycin (50
mg/ml); 293, FHs 738Lu, FHs 173We, SK-Hep1, HepG2, Hep3B,
C33A, Hela and H460 cells were purchased from the American
Type Culture Collection (ATCC). Normal human fibroblast was
recovered from the ascites of patients with liver cirrhosis.
Construction of recombinant adenoviruses
To generate E1B 55 kDa-deleted recombinant adenovirus
(YKL-1), the E1 region from nucleotide 343 to 2,270 in the had5
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genome was amplified using the polymerase chain reaction (PCR)
and pXC1 containing an E1 region (Microbix; Ontario, Canada) as
a template. Primers used were upstream primer, TTATTGGATC-
CTTTGTCTAGGGCCGCGGG, and downstream primer, TCTT-
GGATCCAGATCTATACAGTTAAGCCACCTATACAAC. The
resulting PCR fragment, which included E1A, E1B 19 kDa and a
part of E1B 55 kDa, contained the BamHI site at each 59 and 39
end, BglII at the 39 end for further cloning and premature trans-
lation stop codons in the E1B 55 kDa open reading frame by
substitution of bases 2,253 (C to T) and 2,262 (G to T). The
fragment was digested with BamH1 and cloned into pCA14 shuttle
vector (Microbix; Ontario, Canada), predigested with BglII to
generate pCA14-E1A/E1B 19kDa, and then the sequence was
verified using an ABI PRISM377 automatic DNA sequencer.
pCA14-E1A/E1B 19 kDa shuttle vector and adenovirus vector
pTG-CMV containing the had5 genome, absent in the E1 region
(1341–3535 in nucleotide sequence) and the E3 region (28593–
30469; obtained from Dr. Verca at the University of Fribourgh,
Switzerland) were linealized with XmnI and ClaI, respectively and
cotransformed into BJ5183 E. coli (Chartier et al., 1996). To verify
the proper homologous recombinants, DNAs were purified from
overnight cultures, digested with HindIII and the digestion pattern
was analyzed. The proper homologous recombinant DNA was
digested with PacI and transfected into 293 cells to generate E1B
55 kDa-deleted recombinant adenovirus, YKL-1. Replication-de-
fective counter parts (ad-DE1, ad-DE1/b-galactosidase) and repli-
cation-competent wild-type recombinant adenovirus ad-XJ were
generated by similar manipulation using different shuttle vectors,
pCA14, pDE1sp1A/b-galactosidase, and pXC1, respectively. All
the viruses were plaque-purified, propagated and purified in 293
cells using a standard method (Hitt et al., 1994).
Isolation of viral DNA and PCR analysis
After 2 days postinfection, virus DNA was isolated with a
Qiagen genomic isolation kit (Santa Clarita, CA) from C33A
cervical cancer cells infected with adenovirus at a multiplicity of
infection (MOI) of 10. Five microliters of virus DNA was used for
PCR amplification by using 59 primer, which corresponds to the
upstream sequence of E1A or the upstream sequence of E1B 55
kDa, and 39 primer, which corresponds to downstream sequence of
E1B 55 kDa.
Immunoblotting analysis
Cells were harvested and lysed with lysis buffer (50 mM
HEPES containing 0.15 M NaCl, 0.5% Nonidet P-40 and protease
inhibitors: PMSF, TLCK and TPCK). Pre-cleared lysates corre-
sponding to 105 cells were resolved by 8 or 12% reduced sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred
to PVDF membrane filters (RPN 303F, Amersham, Arlington
Heights, IL). Immunodetection was performed using the Pierce
enhanced-chemiluminescence system (RPN 2108, Amersham)
with 1-–5 mg of mouse monoclonal primary antibody, specifically
recognizing adenovirus E1A (sc-430; Santa Cruz, USA) , E1B 19
kDa (DP17; Calbiochem, San Diego, CA), p53 (MS-186-P1; Neo-
markers, USA) or a-actin (sc-1615; Santa Cruz) proteins.
FIGURE 1 – Characterization of YKL-1. (a) PCR analysis of YKL-1.
Two days post-infection, virus genome was recovered from C33A
cells and PCR was performed using primers corresponding to the
upstream sequence of E1A and the downstream sequence of E1B55
kDa (left panel) or primers corresponding to E1B 55 kDa (right panel).
PCR products were visualized using 1% agarose electrophoresis and
EtBr staining. lane 1, mock infected; lane 2, YKL-1 infected; lane 3,
ad-XJ infected; lane 4, pCA-E1A/E1B 19 kDa (left panel), pXC1
(right panel) as a positive control. (b) Expression analysis of adeno-
virus E1A and E1B 19 kDa protein. Infected cells were harvested and
lysed with cell lysis buffer. Reducing SDS-PAGE was then performed
and E1A and E1B19 kDa were visualized by immunoblotting. lane 1,
293 cells as a positive control; lane 2, mock infected; lane 3, YKL-1
infected. A similar level of a-actin expression indicated that an equal
amount of protein was loaded in each lane.
TABLE I – SUMMARY OF p53 STATUS OF HUMAN CELL LINES USED IN THE STUDY
Cell line Cell type p53 mutation Comments Reference
FHs 173We Fetus lung cells Wild type Normal cells –
FHs 738Lu Embryonic cells Wild type Normal cells –
Human fibroblast Primary fibroblast Wild type Normal cells –
SK-Hep1 Hepatocellular
carcinoma
A partial
deletion or
rearrangement
Bressac B et al. (1990)
HepG2 Hepatoblastoma Wild type Wild type p53 Bressac B et al. (1990)
Hep3B Hepatocellular
carcinoma
Homozygous
deletion
Homozygous deletion Bressac B et al. (1990)
C33A Cervical carcinoma R273C Mutation in DNA-
binding domain of p53
Scheffner et al. (1991)
Hela Cervical carcinoma Wild type HPV positive Scheffner et al. (1991)
H460 Large cell lung
carcinoma
Wild type Wild type p53 Takahashi et al. (1989)
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Luciferase reporter gene assay
Luciferase assays were performed as described previously
(Lee et al., 1999). Briefly, cells in 6-well plates were trans-
fected with p53-luc, which contains a luciferase expression
cassette derived from a p53-responsive element, or pGL-en-
hancer, which contains a luciferase expression cassette derived
from SV40 promoter, together with pcDNA-LacZ (b-galacto-
sidase; Invitrogen), in which LacZ is driven by CMV promoter,
by using Lipofectamine (Gibco BRL) as described in the man-
ufacturer’s manual. Two days post-transfection, the cells were
FIGURE 2 – Virus replication and the cytopathic effect of YKL-1 on a variety of human cancer cells. (a) Cytotoxicity of YKL-1 in human
cancer cells. C33A, Hep3B, SK-Hep1, HepG2, H460 and Hela on 24-well plates were infected with YKL-1, ad-XJ, ad-DE1 or uninfected (UI)
at MOIs of 10, 1 or 0.1. When the cells infected with ad-XJ at an MOI of 0.1 exhibited complete cytolysis, the cells were fixed and stained with
crystal violet. (b) The virus replicating capability of YKL-1 in human cancer cells. Cells were infected with YKL-1 or ad-XJ at an MOI of 10.
Four days post-infection, the virus was recovered and the virus titer was determined by a limiting dilution assay on 293 cells. The amount of
YKL-1 produced was normalized against the amount of ad-XJ produced in the same cells. Values shown represent the mean values of at least
3 independent experiments.
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washed once with phosphate-buffered saline and lysed in 200
ml of reporter lysis buffer (Luciferase assay kit; Promega,
Madison, WI) and luciferase activity was determined as de-
scribed in the manufacturer’s manual with a Luminometer.
Values were normalized to b-galactosidase activity.
Cytotoxicity and virus replication assay
To investigate their cytopathic effect, 2–3 3 104 cells in 24-well
plates (60–80% confluency) at the moment of infection were
infected with YKL-1, ad-XJ or ad-DE1 at an MOI of 10, 1 and 0.1.
They were monitored daily for a cytopathic effect, stained with
0.5% crystal violet in 50% methanol, and analyzed when the cells
infected with ad-XJ at an MOI of 0.1 were essentially cytolysed.
To quantitate virus replication, cells in 6-well plates were infected
with YKL-1 or ad-XJ at an MOI of 10. After 2 or 3 hr, the virus
inoculum was thoroughly washed away and the cells were incu-
bated at 37–C in an incubator for another 3 days. The cell pellets
and supernatants were harvested, viruses were liberated by 3
cycles of freezing/thawing and the virus titer was determined by
limiting dilution assay on 293 cells (Hitt et al., 1994). The relative
virus replication efficiency was calculated by the following equa-
tion as described previously (Heise et al., 1997). (Virus titer in
cells infected with YKL-1/virus titer in cells infected with ad-
XJ) 3 (virus titer in 293 infected with ad-XJ/virus titer in cells
infected with YKL-1) 3 100.
Tumor growth studies in human cancer cell xenograft
Male athymic nu/nu mice were obtained at 5–6 weeks of age.
All animals were housed and handled in accordance with the
Animal Research Committee’s Guidelines at Yonsei University.
After being quarantined for 1–3 weeks, 1 3 107 cells of C33A
cervical cancer or Hep3B hepatoma cells/200 ml of PBS were
injected into the flanks and allowed to grow to 70–80 mm3 (5–8
mm maximal diameter) in tumor volume. The tumors were in-
jected 3 times with 1 3 107 to 109 of live or UV-inactivated
CsCl-purified YKL-1 suspended in 50 ml PBS once every other
day. UV inactivation was completed by exposing 50 ml aliquot of
the purified virus to 3 consecutive cycles of 120,000 microjoules in
a UV Startalinker (Stratagene, La Jolla, CA). Tumor size was
measured twice weekly and the survival rate was determined.
Tumor size was measured by the following equation:
~minor axis!2 3 major axis 3 0.523.
To examine the histology, C33A cervical cancer cell xenografts
were intratumorally injected 3 times with 1 3 108 of live or
UV-inactivated YKL-1 once every other day. Tumors were col-
lected from the 20 day post-infected animals, formalin-fixed and
paraffin-embedded.
H/E staining and TUNEL assay
H/E staining was performed in 6 mm formalin-fixed, paraffin-
embedded tumor sections. Samples were processed according to
FIGURE 3 – Reduced virus replication and the cytopathic effect of YKL-1 in normal human cells. Cells were infected with YKL-1, ad-XJ or
ad-DE1. Then virus production and cytopathic effects were examined, as described in Figure 2. (a) Cytopathic effect of YKL-1 in normal human
cells. (b) Replication capability of YKL-1 in 173We and 738We cells. The amount of YKL-1 produced was compared with the amount of ad-XJ
produced in the same cells. Values represent the means of at least 3 independent experiments.
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the instructions of the ApopTag Kit (Oncor, Inc., Gaithersburg,
MD ) for the detection of cleaved deoxyribonucleic acid in situ,
using the terminal deoxynucleotidyl transferase-mediated de-
oxyuridine 59-triphosphate-biotin nick end labeling (TUNEL)
method.
RESULTS
Construction and characterization of YKL-1
(E1B 55 kDa-deleted adenovirus)
YKL-1, E1B 55 kDa-deleted recombinant adenovirus was
constructed as described in Material and Methods. To confirm
the genotype and phenotype of YKL-1, the presence of E1A and
E1B 19 kDa and the absence of E1B 55 kDa were examined by
PCR and immunoblotting analysis (Fig. 1). Two days after
infection, the virus genome or cell lysates were recovered from
C33A cervical cancer cells infected with YKL-1 or wild-type
ad-XJ at an MOI of 10, by PCR using primers (319/3536),
which cover the entire E1 gene. A 2.0 and 3.2 kb fragments was
generated with YKL-1 or ad-XJ virus genome as templates,
respectively (Fig. 1a, left panel). The 2.0 kb fragment was also
detected with pCA-E1A/E1B 19 kDa shuttle vector under iden-
tical conditions. Furthermore, when the primers covering the
E1B 55 kDa gene (2543/3536) were used, a 1.0 kb fragment
was amplified with the ad-XJ virus genome, but no PCR product
with the YKL-1, indicating that YKL-1 retained only E1A and
E1B 19 kDa in sequence (Fig. 1a, right panel). In addition,
Figure 1b shows that E1A and E1B 19 kDa were readily
detected by immunoblotting when C33A cells were infected
with YKL-1 to a similar level as that of 293 cells expressing E1
gene products. These results indicated that YKL-1 was E1B 55
kDa-deleted recombinant adenovirus.
FIGURE 4 – Endogenous p53 expression/activity in human normal and cancer cells. (a) p53 expression in normal human cells and cancer cells.
Equal amounts of cell lysates were loaded into SDS-PAGE and evaluated by immunoblotting using an antibody to p53. (b) Endogenous p53
transcriptional activity in human cancer cells. Cells were transiently transfected with p53-luc or pGL2-enhancer together with pcDNA-bgal,
which is an indicative of transfection efficiency. Luciferase activity was determined and normalized on the basis of b-galactosidase activities.
The fold increase represents the relative activity of p53-luc vs. pGL2-enhancer in the transfected cells. The values are the averages of at least
3 independent experiments.
458 LEE ET AL.
Virus replication and cytopathic effects of YKL-1 in a variety of
human cancer cells
The characteristics of the cell lines used in our study are sum-
marized in Table I. All 3 different types of normal human cells are
expected to contain wild type p53 in genotype with normal func-
tional activity, whereas human cancer cells employed in our study
exhibited p53 with variable status in the genotype.
To investigate whether YKL-1 is able to replicate and induce
cytopathic effects in human cancer cells, human cancer cell lines
of lung, liver or cervical origin, as shown in Table I, were infected
with YKL-1, wild-type ad-XJ or replication-deficient counterpart
ad-DE1. Virus production and cytopathic effect were examined by
comparison with an ad-XJ infection. Figure 2 shows that C33A or
Hep3B containing inactivated p53 caused by point mutation or
homozygous deletion were readily cytolysed after infection by
both ad-XJ and YKL-1 with a minor reduction in virus production
(55% and 47.5% relative to ad-XJ). In addition, SK-Hep1 with a
rearranged p53 in sequence was found to be relatively sensitive to
YKL-1, with less than one log reduction cytotoxicity and 37% in
virus production. On the contrary, HepG2, Hela and H460 with
wild-type p53 in sequence exhibited a relatively resistant pheno-
type with approximately a 2 log reduction cytotoxicity to YKL-1,
compared with C33A or Hep3B (Fig. 2a). The virus replication
rate of YKL-1 was 30.2%, 16.5% and 2.5% in HepG2, Hela and
H460, respectively (Fig. 2b). In addition, the sensitivity of cancer
cells to YKL-1 was nearly identical to that of ONYX-015 (data not
shown).
Severe attenuation of virus replication and the cytopathic effect
of YKL-1 in normal human cells
To investigate the capability of virus replication and cytolysis of
YKL-1 in normal human cells, FHs 738Lu, FHs 173We and
primary human fibroblast (Table I) were infected separately with
YKL-1, ad-XJ and adDE1, and virus replication and cytotoxicity
was examined as described in Figure 2. All 3 normal human cells
infected with YKL-1, even at the highest MOI of 10, exhibited no
significant cytopathic effects until more than 12 days after infec-
tion, whereas the identical cells underwent complete cytolysis after
infection with ad-XJ within 8 to 12 days at an MOI as low as 0.1
(Fig. 3a). In addition, virus production sharply decreased in the
cells infected with YKL-1, only reaching 0.1 to 1% of ad-XJ in all
3 normal human cells (Fig. 3b). These results, therefore, indicated
that virus production and subsequent cytolysis after infection with
YKL-1 was dramatically attenuated in all 3 normal human cells.
Cytotoxicity and virus production rate of YKL-1 in normal human
cells were substantially lower than that of all the cancer cells
investigated in our study (Figs. 2,3). Attenuated sensitivity of
normal human cells to YKL-1 was nearly comparable to that of
ONYX-015 (data not shown). Therefore, these results showed that
all the human cancer cells examined are more sensitive to YKL-1
with a broad spectrum of sensitivity than normal human cells.
p53 functional status in normal human cells and cancer cells
p53 functional status can be predicted by the endogenous p53
level and its transcription activity without any stimulation (Butz et
al., 1995). To examine whether the status of p53 gene expression
was relevant to the sensitivity of the cells to YKL-1, we investi-
gated the endogenous expression of p53 by immunoblotting anal-
ysis (Fig. 4a). As expected, extremely low levels of p53 were
detected in both normal human cells (FHs 173We and FHs 738Lu)
and cancer cell lines, such as HepG2, Hela and H460, which
contain the wild-type p53 in sequence. On the contrary, p53 was
heavily detected in C33A, which contains an inactivating CGT-
to-TGT (arginine-to-cysteine) mutation at codon 273, due to a
markedly increased half-life of the inactivated mutant p53 (Butz et
al., 1995; Vogelstein and Kinzler, 1992). A higher level of p53 in
SK-Hep1 than in normal cells has been detected previously (Bres-
sac et al., 1990), which is an indicative of abnormal p53 functional
status. p53 could not be detected in Hep3B cells with a homozy-
gous deletion of the p53 gene (Bressac et al., 1990). To measure
the endogenous transcriptional activity of p53, transient transfec-
tion analysis was performed using the p53-responsive luciferase
reporter plasmid (Fig. 4b). H460 and HepG2 expressed 453.5 and
288.2-fold inductions and Hela and SK-Hep1 resulted in 20.7- and
15.6-fold inductions of luciferase activity, while Hep3B and C33A
exhibited only a 1- to 2-fold inductions. Hela is the cervical cancer
cell line infected with human papilloma virus, which results in
abnormal p53 function, which may be inferred by the lower
transcription activity of endogenous p53, compared with H460
(20.7 vs. 435.5-fold inductions; Scheffner et al., 1990).
Next, we investigated the induction rate of p53 by DNA-dam-
aging agents or YKL-1 infection (Fig. 5). The cells were treated
with camptothecin or YKL-1 for variable times and p53 expression
was visualized by immunoblotting. p53 was efficiently induced in
all 3 normal cells, H460 and HepG2 as expected, whereas p53
levels retained high in C33A and were undetectable in Hep3B
regardless of the type of the treatment. Taken together with Figure
4, Figure 5 suggested that the relative sensitivity of different tumor
cells to YKL-1 is considerably correlated with the functionality of
p53.
FIGURE 5 – P53 induction by DNA-damaging agent or YKL-1 infection. C33A, Hep3B, HepG2, H460, 173We and 738Lu were treated with
camptothecin or YKL-1 for variable times as shown above. Cells were harvested and lysed with cell lysis buffer. 10% reducing SDS-PAGE was
performed and p53 was visualized by immunoblotting. Equal amounts of protein were loaded in each lane, which was confirmed by
immunoblotting to the identical blot with a-actin (data not shown). (a) Expression of p53 by 1 mM camptothecin. lane 1, 0 hr; lane 2, 2 hr; lane
3, 4 hr; and lane 4, 8 hr treatment. (b) Expression of p53 by YKL-1 treatment. lane 1, 0 hr; lane 2, 24 hr, and lane 3, 36 hr infection.
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Antitumoral efficacy of KL-1 in nu/nu mice.
To demonstrate the antitumoral effects of YKL-1, tumor growth
was determined after YKL-1 was injected intratumorally into
C33A (Fig. 6) or Hep3B (Fig. 7) tumor xenografts in nu/nu mice.
Significant inhibition of tumor growth in both C33A and Hep3B
xenografts was observed in the experimental group with live
YKL-1 compared with UV-inactivated YKL-1, which was used as
the control group. As more live YKL-1 was injected, more pro-
found growth inhibition was detected (Fig. 7a). In addition, an
increased animal survival rate was observed in both xenografts,
and 4 out of 6 animals that received injections of YKL-1 at 1X109
PFU in Hep3B xenograft were tumor-free for 2 months after
complete tumor regression (data not shown). H/E staining clearly
indicated the profound necrosis in C33A (Fig. 6b) and Hep3B
(data not shown) tumor xenograft with live YKL-1. In addition, we
did not detect any significant tissue damage caused by adenovirus
infection in the surrounding normal tissue. TUNEL assay (Fig. 7b)
showed that active apoptosis occurred in the surrounding necrotic
area, implying that an apoptotic event was probably one of the
reasons for the regression of the Hep3B xenograft by YKL-1 (Fig.
7a). Therefore, these results demonstrate that the antitumoral ef-
fect of E1B 55 kDa-deleted YKL-1 adenovirus is dose dependent
and induced by tumor necrosis and apoptosis following intratu-
moral administration.
DISCUSSION
Preferentially replication-competent adenovirus in tumor cells,
but not in normal cells, is a highly attractive option, because it is
unlikely that cancer gene therapy based on replication-defective
adenovirus would be effective against large tumor masses in most
human cancer patients. In our study, we generated E1B 55 kDa-
deleted adenovirus YKL-1, which was confirmed by DNA se-
quencing, restriction enzyme digestion, PCR and immunoblotting
analysis, and then we investigated its potential as an oncolytic
adenoviral vector.
The therapeutic efficacy of E1B-attenuated adenovirus ONYX-
015 for cancer treatment has been investigated previously
(Bischoff et al., 1996; Heise et al., 1997) and YKL-1 exhibited a
similar pattern of therapeutic efficacy to ONYX-015 in vitro and in
vivo in this investigation. The E1B 55 kDa-deleted adenovirus
(YKL-1) we generated is distinct from ONYX-015 in construction
strategy and genomic structure. Instead of deleting a portion of
E1B 55 kDa, it was generated by reintroducing E1A and E1B 19
FIGURE 6 – Effect of YKL-1 on C33A xenograft. 13107 cells were injected subcutaneously into the flanks of nu/nu mice. Once tumor volume
reached about 80 ml in size, live or UV-inactivated YKL-1 was injected. Live or UV-inactivated YKL-1 of indicated PFU was injected 3 times
intratumorally once every other day. Tumor growth was measured 3 times weekly by a caliper until the end of the study. Relative tumor growth
was analyzed using the following equation: tumor volume at the time point of analysis/tumor volume at the time of the first virus injection. (a)
Antitumoral effect of live YKL-1. (b) H/E staining. Fifteen days after the injection of live or UV-inactivated YKL-1, the animals were sacrificed
and H/E staining was carried out in formalin-fixed paraffin-embedded tumor sections. Tumor specimens injected with UV-inactivated YKL-1
(left panel) demonstrated active proliferation of tumor cells and the specimen injected with live YKL-1 (right panel) exhibited tumor necrosis.
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kDa genes into E1/E3-deleted adenoviral vectors, which resulted
in a larger deletion in E1B 55kDa than ONYX-015 (1,260 bp; 84%
deletion of E1B 55 kDa vs. 827 bp). In addition, YKL-1 contains
a 1.7 kb additional deletion in the E3 region, which provides
higher capacity for the insertion of a foreign gene (4.9 kb vs.
2.7kb), and thereby provides enough space for various therapeutic
gene expression cassettes. Finally, therapeutic genes can be easily
inserted into YKL-1 vector at the BglII site, which was created at
the 39 end of restored E1.
The virus replication and cytotoxicity of YKL-1 was markedly
attenuated in all 3 normal human cells examined in our study,
which corresponds to at least a 2–3 log difference compared with
that of wild-type adenovirus (Fig. 3). By contrast, under identical
conditions, YKL-1 replicated and induced a cytopathic effect in all
cancer cells with a broad spectrum of sensitivity (Fig. 2). These
results indicated that the oncolytic potential of the YKL-1 is a
reminder of a preferential cytotoxicity of ONYX-015, which con-
firms previously published reports concerning the ability of an
E1B 55 kDa-deleted adenovirus to selectively replicate in most
human cancer cells (Heise et al., 1997; Vollmer et al., 1999). In
addition, the growth inhibition of both C33A and Hep3B xenograft
in nu/nu mice was evident in a dose-dependent manner, by the
intratumoral injection of YKL-1. H/E staining implied that severe
necrosis was caused by live YKL-1, and TUNEL staining in the
Hep3B xenograft indicated that active apoptosis on the periphery
of the necrotic area was also induced by live YKL-1 (Fig. 6). This
FIGURE 7 – Effect of YKL-1 on Hep3B xenograft. Hep3B xenograft was prepared and live or UV-inactivated YKL-1was administrated as
described in Figure 6. (a) Relative tumor volumes by differently administered viral doses. (b) Tunnel assay of Hep3B human tumor xenografts.
Fifteen days after the injection of live (right panel) or UV-inactivated YKL-1 (left panel), animals were scarified and TUNEL assay was
conducted in formalin-fixed paraffin-embedded tumors. The right panel demonstrates numerous apoptotic cells.
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result indicated that YKL-1 retaining E1B 19 kDa (which is well
known for its anti-apoptotic properties) can drive apoptosis and
initialize Hep3B cell death in the absence of functional p53 (Shen
and Shenk, 1994). E1A oncogene has been identified to induce
cellular apoptosis via p53 dependent and independent mechanisms
(Shenk, 1996; Nakajima et al., 1998; Cook et al., 1999). Further-
more, E1A induced apoptosis via the p53 independent pathway
was found to be resistant to blockage by E1B 19 kDa (Cook et al.,
1999).
Recently, there has been a number of reports, which have raised
questions about the use of E1B 55 kDa-deleted adenovirus in
cancer gene therapy, by demonstrating a weak correlation between
the p53 status of the cells and virus production, virus gene expres-
sion and the cytopathic effect of E1B 55 kDa-deleted adenovirus
agent (Hall et al., 1998; Goldsmith et al., 1998; Goodrum and
Ornelles, 1998; Rothmann et al., 1998; Harada and Berk, 1999;
Hay et al., 1999; Turnell et al., 1999). However, there are several
points, which should be addressed. Firstly, studies on the selectiv-
ity by p53 in most cases have relied on sequence information to
determine the status of p53 in cancer cells, but it is widely accepted
that as a multifunctional transcription modulator, p53 is at least
partially nonfunctional in most cancer cells beyond the p53 se-
quence (Chang et al., 1995; Leach et al., 1993; Marchetti et al.,
1995; Scheffner et al., 1990; Joseph and Vogt, 1996). In fact, our
data supports the notion that the oncolytic potential of E1B 55
kDa-deleted adenovirus seems to be significantly related to the
endogenous p53 functional status in both human normal cells and
cancer cells (Figs. 2–5). All 3 different types of normal human
cells examined in our study with functional p53 exhibited a resis-
tant phenotype to YKL-1 in terms of both virus replication and
resultant cytolysis (Figs. 3– 5). Moreover, Hep3B and C33A
cancer cells, with aberrant p53, which is indicated by the lack of
induction of p53 after treatment with camptothecin or YKL-1,
exhibit the most sensitive phenotype to YKL-1. HepG2 and H460
were found to possess indistinguishably functional p53, compared
with that of human normal cells in current study (Figs. 4,5). Yet,
these cancer cells were more sensitive to YKL-1 than normal
human cells (Figs. 2,3). These results may imply that p53 is
partially inactivated in HepG2 and H460, which we were not able
to detect in our study. The other possibility is that human cancer
cells are more sensitive to YKL-1 by some other mechanism.
Secondly, most studies on the potential of E1B-deleted adenovirus
have been carried out on cancer cells only and focused on cyto-
toxicity or virus replication at a very early stage of infection with
high MOI. This condition may not allow enough time or a proper
environment for the virus to selectively replicate and result in a
cytopathic effect. Thereby, this may cause limitations in terms of
properly representing the practical situation in the tumor mass with
infections induced at low MOIs, due to an unevenly distributed
virus load. In fact, Vollmer et al. (1999) recently reported that p53
selective replication of an E1B-deleted adenovirus in hepatocellu-
lar carcinoma occurs only at a low viral dose. Nevertheless, the
correlation between p53 functional status and the oncolytic poten-
tial of E1B 55 kDa-deleted adenovirus needs to be explored more
extensively and the use of E1B 55 kDa-deleted adenovirus should
be carefully verified in vitro and in vivo in each cancer model.
Recently, Wildner et al. generated E1B 55 kDa-deleted adeno-
virus expressing herpes simplex virus-thymidine kinase (HSV-TK)
and exhibited much-improved therapeutic efficacy in a human
cancer xenograft model (Wildner et al., 1998, 1999). In addition,
Freytag et al. suggested the possibility of combining oncolytic
potential, suicidal gene therapy (HSV-TK and CD) and radiother-
apy (Freytag et al., 1998). Finally, Heise et al. showed that the
therapeutic efficacy of E1B 55 kDa-deleted adenovirus could be
augmented by standard chemotherapeutic agents, such as cisplatin
or 5-FU (Heise et al., 1997). YKL-1 infection also enhanced the
cytotoxicity of cancer cells to chemotherapeutic agents, including
adriamycin, but not in normal cells (data not shown).
Coupled with the data presented here, E1B 55 kDa-deleted
adenovirus YKL-1 seems to offer promising potential as an onco-
lytic agent and as a selectively replication-competent adenovirus
vector capable of delivering therapeutic genes preferentially into
tumor cells.
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